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Abstract
Prostate imaging and interpretation is based on prostate imaging reporting and data system version 2 (PI-RADS™ v2)
providing clinical guidelines for multiparametric magnetic resonance imaging (mpMRI) of the prostate. PI-RADS™ v2
aims to promote global standardisation, to diminish variation in the acquisition, interpretation and reporting of
prostate mpMRI examinations and to improve detection, localisation, and risk stratification in patients with suspected
cancer in treatment naïve prostate glands. It does not address detection of recurrence, progression during active
surveillance and evaluation of other parts of the body.
PI-RADS™ v2 improves and standardises communication between radiologists and urologists to detect or exclude the
presence of significant prostate cancer with a high likelihood. Findings on mpMRI are assessed on a 5-point category
scale based on the probability that a combination of findings on T2-weighted (T2w) sequences, diffusion-weighted MRI
(DWI) and dynamic contrast-enhanced MRI (DCE-MRI) correlates with the presence of a clinically significant prostate
cancer at a particular location. PI-RADS assessment categories range from 1 to 5 with 5 being most likely to represent
clinically significant prostate cancer. The dominant sequence to detect prostate cancer in the peripheral zone is DWI,
whereas for tumour detection in the transition zone T2w is the most important sequence. DCE-MRI has been attributed
a minor role and only qualitative assessment with presence or absence of focal enhancement is suggested. Up to four
suspicious lesions of category 3, 4 and 5 are assigned on a sector map and the index lesion should be identified.
Keywords: Prostate cancer, Multiparametric magnetic resonance imaging (mpMRI), Prostate Imaging Reporting and
Data System version 2 (PI-RADS™ v2)
Introduction to clinical context and proposed
utility of modality
Prostate cancer is the second most common cancer in
men worldwide [1]. Two thirds of prostate cancer cases
are diagnosed in the more developed regions of the
world. The incidence varies over a broad range among
different countries probably as a result of a difference in
the number of men screened. Mortality of prostate
cancer is difficult to measure due to the mortality of
concomitant cardiovascular diseases and other cancers
which share similar risk factors and therefore act as
confounders. The prevalence of latent prostate cancer at
autopsy is high and occult carcinomas are common [1].
According to two big screening studies “Prostate cancer
screening in the randomized Prostate, Lung, Colorectal,
and Ovarian Cancer Screening Trial” (PLCO) [2] and
“Screening and prostate cancer mortality: results of the
European Randomised Study of Screening for Prostate
Cancer” (ERSPC) [3] overdiagnosis is common, therefore
screening for prostate cancer is controversial. Prostate
cancer screening is based on digital rectal examination
(DRE) and prostate-specific antigen (PSA) level testing
in the blood serum. PSA is highly sensitive but not
specific for prostate cancer. Benign pathologies such as
benign prostatic hyperplasia can raise PSA levels and
normal PSA levels can not exclude prostate cancer [4].
Prostate biopsies are assessed histologically by the
Gleason score, a prognostic factor of prostate cancer,
which provides information on tumour aggressiveness
[5]. Prostate cancer is divided into clinically insignificant
and significant prostate cancer, depending on its likeli-
hood to affect a patient’s lifetime. There is no universal
definition for clinical significant prostate cancer, but the
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most frequent applied definition is the following:
Pathology/histology with Gleason score≥ 7 (including 3 + 4
with prominent but not predominant Gleason 4 compo-
nent), and/or volume ≥ 0.5 cc, and/or extra prostatic exten-
sion (EPE) [6]. Depending on the Gleason score and
clinical assessment of the patient’s disease, treatment op-
tions for prostate cancer are active surveillance, surgery
and radiotherapy [7].
MRI became the method of choice for detection and
staging of prostate cancer [8]. Adapted from breast
imaging a “Prostate Imaging Reporting and Data System”
(PI-RADS) was published by the European Society of
Urogenital Radiology (ESUR): PI-RADS™ version 1 [9]
(PI-RADS™ v1). This first guideline paper was based on
a summary score for each lesion assessed in different
sequences of mpMRI, consisting of T2w, DWI and
DCE-MRI and spectroscopy facultatively. These guide-
lines have been updated recently by a steering commit-
tee including the American College of Radiology (ACR),
ESUR and the AdMeTech Foundation to the PI-RADS™
v2 [10, 11]. In this version spectroscopy was omitted and
DCE-MRI was attributed a minor role. In contrast to
version 1 each lesion is attributed a single score based
on findings of mpMRI. The objectives of these guidelines
were to promote global standardisation of prostate
imaging, to improve detection, localisation, characterisa-
tion, risk stratification of prostate cancer in treatment
naïve prostate as well as to improve communication
with referring urologists. The latest PI-RADS version
assesses the likelihood (probability) of clinically signifi-
cant prostate cancer on a 5-point scale for each lesion as
follows:
 PI-RADS 1 – Very low (clinically significant cancer
is highly unlikely to be present)
 PI-RADS 2 – Low (clinically significant cancer is
unlikely to be present)
 PI-RADS 3 – Intermediate (the presence of clinically
significant cancer is equivocal)
 PI-RADS 4 – High (clinically significant cancer is
likely to be present)
 PI-RADS 5 – Very high (clinically significant cancer
is highly likely to be present)
For corresponding examples of findings see Fig. 1.
Up to four findings of category 3, 4 or 5 on mpMRI
are mentioned and the index (dominant) lesion with the
highest PI-RADS assessment category is determined. A
final PI-RADS score is reported for each lesion.
Indications for prostate MRI include patients with
clinical suspicion of prostate cancer (elevated PSA >
4.0 ng/mL and/or suspicious DRE) before biopsy for
tumour detection or exclusion, patients with known
prostate cancer for staging purposes (scheduled for
treatment with curative intent or active surveillance) as
well as patients with a negative biopsy but continuous
clinical suspicion of prostate cancer.
MRI serves as an instrument for detection and/or
staging of prostate cancer at the same time. In case of a
suspicious lesion detected on MRI, targeted MRI-
transrectal ultrasound (TRUS) fusion guided transperineal
or transrectal biopsy is performed after meticulous
demonstration of the findings to the referring urologist, as
previously described [12].
Detection of recurrence after radiotherapy or radical
prostatectomy, progression during active surveillance or
for detection of metastases outside the pelvis are not
considered in PI-RADS™ v2.
MRI not only offers an excellent resolution of the
prostatic gland, but also evaluates locoregional extension,
pelvic lymph nodes involvement and bone metastases
in the pelvis. Ultrasound alone has too poor spatial
resolution to suffice as an adequate imaging method.
C11- and F18- choline positron emission tomography
(PET) are other imaging methods used for detection
of recurrence or metastatic disease in prostate cancer,
but not for detection of the primary tumour or local
staging. New tracers, such as Ga68 prostate-specific
membrane antigen may play a role in prostate cancer
imaging in the future as well as a combination of
PET/MRI [13].
MRI protocol
Patients with contraindications for MRI have to be
excluded. If possible patients should evacuate the rectum
just prior to the MRI exam. For reduction of bowel
motion artefacts an antispasmolytic agent is adminis-
tered. MRI of the prostate is performed according to the
PI-RADS™ v2 guidelines on a 3 T scanner without an
endorectal coil. The prostate including the seminal vesi-
cles are imaged as follows with a reduced field of view:
Axial high-resolution T2w sequence with the following
imaging parameters: Repetition time (TR) = 3710 msec,
echo time (TE) = 113 msec, slice thickness = 3 mm, pixel
size = 0.4 × 0.4 mm, field of view (FoV) = 220 mm and
acquisition time (TA) = 4 min 29 s.
Axial DWI sequence with b-values of 0, 500, 1000,
1500 and 2000 s/mm2 and with the following imaging
parameters: TR = 4700 msec, TE = 93 msec, slice thick-
ness = 3.5 mm, pixel size = 3.1 × 3.1 mm, FoV = 160 mm
and TA = 6 min 37 s.
Axial DCE-MRI sequence with a standard, preferable
macrocyclic, gadolinium based contrast agent adminis-
tered with a dose of 0.1mml/kg. Injection rate is 2.5 cc/s
starting with continuous image data acquisition with a
temporal resolution of 3.4 s and acquisition time up to
283.5 s. Imaging parameters are as follows: TR = 4.22 msec,
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TE = 1.35 msec, slice thickness = 3.5 mm, pixel size = 1.4 ×
1.5 mm, FoV = 220 mm and TA = 4 min 46 s.
A precontrast T1w sequence is needed to exclude
haemorrhage. We perform it from the aortic bifurcation
to the pubic symphysis with the following imaging
parameters: TR = 3.92 ms and TE = 1.24 msec, slice
thickness = 2 mm, pixel size = 1.3 × 1.8 mm, FoV =
400 mm and TA = 21 s. In addition a high resolution
T2w sequence should be performed in the coronal and
sagittal plane. We prefer a 3D coronal T2w sequence of
a b
Fig. 1 PI-RADS™ v2 assessment categories: Fig. 1a depicts typical findings in the peripheral zone and Fig. 1b depicts typical findings in the transition
zone. a. Peripheral zone shows PI-RADS assessment categories with DWI as dominant sequence. 1. No abnormality (i.e. normal) on the high b-value
DW image and on the corresponding ADC map as well as on the T2w image. 2. Isointense signal of the peripheral zone on the high b-value DW
image with an indistinct linear hypointense lesion on the ADC map (arrow) with corresponding T2w hypointense signal. 3. Isointense/mildly hyperintense
signal of the peripheral zone on the high b-value DW image and with a focal mildly/moderately hypointense indistinct lesion on the
ADC map (arrow). T2w image shows heterogeneous signal intensity of the peripheral zone. 4. Focal markedly hyperintense lesion on high
b-value DW image with corresponding markedly hypointense signal intensity on the ADC map (arrow). Lesion size is < 1.5 cm on axial images. T2w
image shows a circumscribed homogenous hypointense lesion. 5. Same as 4, but lesion size is≥ 1.5 cm in greatest dimension (arrow). Definite
extraprostatic extension/invasive behaviour (not shown) would also qualify for this category. b Transition zone shows PI-RADS assessment categories
with T2w as dominant sequence: 1. Homogeneous intermediate signal intensity (normal) on T2w image and no abnormality on high b-value DW
image and ADC map. 2. Circumscribed (arrows) hypointense or heterogeneous encapsulated nodule(s) (BPH). High b-value DW image shows normal
signal intensity and indistinct hypointense signal on ADC map. 3. Lesion with heterogeneous signal intensity with obscured margins (arrow). High
b-value DW image of the lesion is mildly hyperintense and moderately hypointense on the ADC map. This category includes lesions that do not qualify
as 2, 4, or 5. 4. Lenticular (arrow) or non- circumscribed, homogeneous, moderately T2w hypointense lesion, < 1.5 cm in greatest dimension. High
b-value DW image of the lesion shows markedly hyperintense signal and markedly hypointense signal on the ADC map. 5. Same as 4, but lesion size
is≥ 1.5 cm in greatest dimension (arrows). Definite extraprostatic extension/invasive behaviour (not shown) would also qualify for this category
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the pelvis with an isotropic voxel of 1 mm to allow
reconstruction in the axial and the sagittal plane.
Imaging parameters are as follows: TR = 1500 msec,
TE = 122 msec, slice thickness = 1 mm, pixel size = 1.0 ×
1.0 mm and FoV = 380 mm and TA = 7 min 2 s. This
sequence includes the aortic bifurcation and the pubic
symphysis and facilitates reconstruction in any plane
especially for lymph node staging in combination with
an additional DWI sequence of the entire pelvis with
b-values of 0, 500, 1000 s/mm2 and with the following
imaging parameters: TR = 10300 msec, TE = 50 msec, slice
thickness = 4 mm, pixel size = 3.1 × 3.1 mm, FoV =
420 mm and TA = 5 min 03 s.
All sequences are acquired without breath-hold. For
ADC map calculation b-values (0 - 1000 s/mm2) were
used.
Finally, though not part of the PI-RADS™ v2 guide-
lines, the entire pelvis is scanned after contrast medium
administration with an isotropic T1w fat saturated
sequence with a voxel size of 1.2 mm. The reason for
this additional sequence is to better evaluate other extra-
prostatic findings.
Display of images
Ideally two 21.0 inch or one 30.0 inch standard
radiology monitor for image display with a resolution
of at least 3 megapixels and a contrast ratio of at
least 750:1 should be available. Additional monitors
for reporting and other activities e.g. PACS steering,
Internet, reference databases are recommended.
Depending on the software, which is used, morpho-
logic and functional sequences should be displayed at
the same time. For a first overview axial T2w images
are recommended. On the left side we display the
morphologic T2w images. On the right side DWI is
displayed, i.e. b-value images and ADC-map at the
same time. Ideally the morphologic and the func-
tional images should be linked at the same table
position. With this described display mode, in many
cases a final diagnosis of the primary tumour can
already be made according to PI-RADS™ v2. In
addition, DCE-MRI is displayed in a continuous stack
of images at different time points and table positions.
For exact morphologic localisation of suspicious
lymph nodes and level of the prostatic lesion
isotropic voxel 3D T2w sequence can be reformatted
at user's preferences [14]. Additionally fused images
of morphology and functional maps may be helpful
for exact localisation of findings. A standard layout of
our prostate image display is shown in Fig. 2.
Image interpretation
Image analysis is based on DWI, DCE-MRI and on T2w
sequences. Pattern recognition on these sequences is
primarily defined by the criteria of the PI-RADS™ v2
guidelines (Fig. 3) and findings should be described
according to the lexicon in appendix III of PI-RADS™ v2
guidelines. Before starting image interpretation, the
quality of the images has to be assured. Artefacts like
metal implants (e.g. hip prosthesis), air in the rectum
and patient movements can compromise the diagnostic
value of images. When DWI or DCE-MRI are inad-
equate, PI-RADS™ v2 guidelines advise to use substitute
sequences as described in caption of Fig. 3.
Fig. 2 Standard layout of our prostate image display in a one screen setting. Double clicking in one of the images allows to display this image in
full screen mode
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Fig. 3 (See legend on next page.)
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The prostate should be analysed for focal lesions in
the prostate and seminal vesicles. Peripheral zone and
transition zone are assessed separately as depicted in
Fig. 3. Due to the fact that 70-75 % of prostate cancers
arise in the peripheral zone, we recommend to start
viewing functional images first. In the peripheral zone
the dominant sequence is DWI. Suspicious lesions typic-
ally have a hyperintense signal intensity on high b-value
DW images and a hypointense signal intensity on the
corresponding ADC maps. In case a lesion on DWI
reveals PI-RADS assessment category 3, the lesion is
further assessed on DCE-MRI as positive or negative.
DCE-MRI is evaluated as positive, when visual assess-
ment, by either manually scrolling or using cine mode,
reveals a focal, earlier or a contemporaneous enhance-
ment to adjacent normal prostatic tissue, and usually
corresponds to a suspicious finding on T2w and/or
DWI. When such positive findings are detected in a
lesion corresponding PI-RADS assessment category 3 on
DWI in the peripheral zone, the PI-RADS assessment
category is uprated from 3 to 4. Otherwise if DCE-MRI
is negative for a lesion in the peripheral zone with PI-
RADS assessment category 3 the lesion remains 3.
In the transition zone T2w is the dominant sequence.
Suspicious lesions have a heterogeneous signal intensity
with obscured margins, lenticular or non-circumscribed
homogeneous moderately hypointense signal intensity on
T2w images. In case a lesion on T2w imaging reveals PI-
RADS assessment category 3, the lesion is further assessed
on DWI. When DWI shows markedly hyperintense signal
intensity on high b‐value DW images and hypointense sig-
nal intensity on the corresponding ADC map of the lesion
and the greatest dimension is ≥ 1.5 cm, the lesion is uprated
to PI-RADS assessment category 4. All lesions showing
EPE and/or invasion of the seminal vesicle correspond to
PI-RADS assessment category 5. EPE is defined as a lesion
extending to an area outside of the prostate or bulging the
capsule of the prostate. Invasion of the seminal vesicle is
defined as tumour extension into the seminal vesicle.
Thereafter, the entire pelvis should be analysed for lymph
node involvement, bone metastases and other findings.
Especially DWI sequences of the entire pelvis in
combination with meticulous analysis of 3D T2w
sequences help to detect lymph node metastases [14].
Pitfalls in prostate cancer imaging can be categorised as
previously described [15, 16].
a) Normal anatomic structures that may be mistaken
for tumour:
Peripheral zone lesions can be mimicked by normal
central zone or periprostatic venous plexus or
neurovascular bundle. Bilateral T2w image
hypointensities at the base and/or median posterior
T2w image hypointense area in the middle third of
the gland can mimic peripheral zone lesions.
Asymmetric thickening of the surgical capsule can
be difficult to distinguish from a focal lesion.
b) Noncancerous abnormalities that can mimic tumour:
Postbiopsy haemorrhage is a pitfall, which can be
avoided when PI-RADS™ v2 guidelines are applied
correctly and MRI is performed more than 6 weeks
after biopsy. The differentiation between stromal
benign prostatic hyperplasia and a transition zone
tumour can be very difficult. Protrusion of a benign
prostatic hyperplasia (BPH) nodule can mimic a
peripheral zone lesion. Acute and chronic prosta-
titis, postinflammatory scars and atrophy mimick-
ing tumour is less difficult to distinguish, due to
characteristic patterns on T2w sequences. With-
out adequate clinical information, granulomatous
prostatitis is another mimicker of a tumour and
can not be differentiated based on imaging
alone.
c) Technical challenges related to DWI:
Anatomic distortion of high b-value DW images
can lead to obscuration of focal lesions. Lack of
suppression of benign prostate tissue on standard
high b-value DW images is another pitfall, which
leads to false positive findings. On the other side,
suboptimal windowing of ADC maps can yield false
negative results.
Experience, meticulous image analysis, including
morphological and functional images at the same time
are factors, which can reduce false positive results.
Formulating reports
Reporting at our institution is performed in a structured
way on a free text basis. All patients undergoing MRI-
TRUS fusion guided biopsy are reported additionally by
one senior radiologist specialised in genitourinary radi-
ology on a template scheme map for biopsy planning. This
scheme map is further demonstrated to the biopsy
(See figure on previous page.)
Fig. 3 The predominant sequence is DWI in the peripheral zone and T2w sequence in the transition zone. In case of PI-RADS assessment category 3
in the peripheral zone DCE-MRI determines the final PI-RADS assessment category and in PI-RADS assessment category 3 in the transition zone DWI
determines the final PI-RADS assessment category. When image quality is compromised and DCE-MRI is inadequate for the assessment of
the peripheral zone in PI-RADS assessment category 3 the PI-RADS score is defined by DWI alone. If DWI is not adequate PI-RADS™ v2
guidelines advice use of T2w sequence for both, the peripheral zone and for the transition zone. If both DWI and DCE-MRI are inadequate or not
available, assessment should be limited to staging for determination of EPE [11]
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performing urologist. According to PI-RADS™ v2 appen-
dix II report templates are under construction. We are
looking forward to integrating report templates in
computer-aided evaluation soon. Software for computer-
aided structured reporting is already on the market for PI-
RADS™ v1 and will soon be available for PI-RADS™ v2.
A prostate MRI report should be structured with the
following italic subheadings:
Clinical notes
According to PI-RADS™ v2 the following information
should be available at the time of the exam: PSA and
PSA history; information on previous biopsies and
corresponding Gleason score; previous surgery and other
relevant clinical history of the prostate.
Technical details
In this section patient preparation, field strength of the
MR scanner, amount and name of contrast medium are
mentioned. As the prostate MRI protocol for PI-RADS™
v2 reporting is standardised no further technical details
are mentioned. If quality of DWI or DCE-MRI is not ad-
equate, causes of problems should be mentioned in this
section and, if possible, performed solutions should be
reported in order to perform eventual follow-up studies
of the same patient with identical sequence alterations.
Findings
In our institution reports start with the prostate volume
and an overall impression of the prostatic gland. The pros-
tate gland volume is calculated using the formula for a
conventional prolate ellipse: (maximum anterior posterior
diameter) x (maximum transverse diameter) × (maximum
longitudinal diameter) x 0.52. Findings are described
according to PI-RADS™ v2 separately for peripheral zone
and transition zone. Lesions are characterised in size,
localisation, signal intensity, homo-/heterogeneity, border
configuration, possible EPE and possible infiltration of the
neurovascular bundle and seminal vesicles as well as
infiltration of adjacent organs are reported in this section.
Up to four findings based on PI-RADS™ v2 assess-
ment category of 3, 4 or 5 are described and the
index (dominant) lesion is identified. Presence or ab-
sence of possible lymph node metastases in the entire
pelvis are described and exact localisation, number
and size are mentioned. Additionally, if present, bone
metastases are described. Finally, additional findings
in the scanned volume are mentioned.
Fig. 4 Clinical Notes: Actual PSA: 27.5 ng/ml; PSA last year: 31.4 ng/ml. One year previous prostate biopsy revealed no cancer.
Technical Details: Standard prostate MRI protocol, 3 T MRI scanner, 16 ml Multihance.
Findings: Enlarged prostate of circa 43 ml (44 mm × 51 mm × 37 mm × 0.52). Peripheral zone: Midlevel on T2w image depicts a focal lesion of
20 mm maximal extension (PI-RADS 5) (white arrows). The lesion shows a high signal intensity in the anterior fibromuscular stroma and
in the left peripheral anterior zone on the high b-value DW image (white arrowheads) with corresponding low signal intensity on the
ADC map (black arrowheads) (ADC ~580 × 10−6mm2/s) (PI-RADS 5). DCE-MRI is rated positive, showing a focal enhancement, earlier than
adjacent prostate tissue (black arrows). Transition zone: Circumscribed hypointense encapsulated nodules (BPH) (PI-RADS 2). No suspicious
locoregional or pelvic lymph nodes. No suspicious bone lesions. No additional findings.
Conclusion: Clinically significant prostate cancer is highly likely to be present in the anterior fibromuscular stroma and in the left peripheral anterior
zone in the midlevel with greatest dimension≥ 1.5 cm corresponding to PI-RADS 5. No suspicious lymph nodes or bone lesions.
Histology: MRI-TRUS fusion guided biopsy revealed Gleason score 4 + 3 = 7
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Key findings are especially described with exact
localisation according to PI-RADS™ v2 Appendix III
sector map.
Conclusion
For each lesion of category 3, 4 and 5 the likelihood for
presence or absence of clinically significant prostate cancer
is depicted and the exact localisation is mentioned. The
corresponding PI-RADS™ v2 score is specified. Presence or
absence of extraprostatic extension, lymph node involve-
ment and bone metastases is always explicitly mentioned.
Two cases and corresponding scheme maps and reports
are shown in Figs. 4 and 5.
Conclusion
Review and reporting of prostate MRI adheres strictly to
PI-RADS™ v2 guidelines. Prostate cancer imaging is
based on mpMRI, consisting of T2w sequences, DWI
and DCE-MRI. Findings on mpMRI are assessed accord-
ing to the PI-RADS™ v2 5-point category scale. Up to four
suspicious lesions of category 3, 4 and 5 of PI-RADS™ v2
are identified and for each lesion the corresponding likeli-
hood (probability) of clinically significant prostate cancer
is specified.
Prostate MRI in our institution is performed before
MRI-TRUS fusion guided biopsy. In this setting prostate
MRI is used for detection and/or staging at the same
time. One might even speculate that, when image acqui-
sition gets faster and the cost of examination falls, MRI
might be even be used for prostate cancer screening in
the future.
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